[DNA vaccine].
The study of DNA vaccine has been started after the initial report showing that plasmids encoding a reporter gene are able to induce in vivo expression of the encoded protein. While some of DNA vaccines have already been tested in clinical trials, a lot of new methods and technologies to augment the immunogenicity of DNA vaccines are under evaluation in preclinical studies. We examined two approaches incorporating helper antigens or co-stimulatory molecules in CTL antigen and showed the enhancement of tumor antigen-specific CD8+ T cell induction and in vivo tumor rejection capacity. These data and the recent approaches may provide us an important hint for establishing new therapeutic vaccines.
Nishikawa
Hiroyoshi
H
Department of Cancer Vaccine, Mie University Graduate School of Medicine.
Shiku
Hiroshi
H
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018984:Epitopes, T-Lymphocyte; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010957:Plasmids / Q000276:immunology; D048069:Tumor Necrosis Factors / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use
D018984:Epitopes, T-Lymphocyte; C478966:Tnfsf18 protein, mouse; D048069:Tumor Necrosis Factors; D019444:Vaccines, DNA